Table of updates: Recommendations on the use of COVID-19 vaccines
This table summarizes the updated information provided in each version of the Recommendations on the use of COVID-19 vaccines document page since the publication of the first version on December 12, 2020.
For previous versions of the COVID-19 vaccine statement, visit the archives.
Recommendations on the use of COVID-19 vaccines
Published January 12, 2021
|Dose, route of administration, and schedule||Section on "Delay in receipt of dose 2 in a COVID-19 vaccine series" has been updated to include calculated vaccine efficacy estimates of COVID-19 vaccines after the first dose.||2021-01-12|
|Recommendations||Options for the administration of a complete COVID-19 vaccines series to maximize population health benefits in the context of vaccine delivery, epidemiological, and healthcare system capacity considerations have been added.||2021-01-12|
|Recommendations||Recommendations for immunosuppressed persons, persons with an autoimmune condition, and pregnancy and breastfeeding have been revised for clarity.||2021-01-12|
|Management Options||A section of management options for COVID-19 immunization program roll-out in the context of limited vaccine supply has been added. This section summarizes available evidence and considerations with decision points to guide jurisdictions in the roll-out of an effective, efficient, and equitable COVID-19 immunization program.||2021-01-12|
|Appendix A||Calculated vaccine efficacy estimates of the Pfizer-BioNTech COVID-19 vaccine after the first dose have been added.||2021-01-12|
|Appendix B||Calculated vaccine efficacy estimates of the Moderna COVID-19 vaccine after the first dose have been added.||2021-01-12|
Recommendations on the use of COVID-19 vaccines (addition of Moderna COVID-19 vaccine) (version now archived)
View the archived version.
Published December 23, 2020
All sub-sections under Vaccines have been updated to include evidence or information from the product monograph related to the Moderna COVID-19 vaccine. This includes:
|Dose, route of administration, and schedule||Additional clarifying information on the schedule for a complete mRNA COVID-19 vaccine series has been added.||2020-12-23|
|Interchangeability||Additional information on the interchangeability of mRNA vaccines and guidance in case of limited supply or unavailability of a particular product has been incorporated under the NACI recommendation on interchangeability.||2020-12-23|
|Recommendations||Recommendations on COVID-19 vaccine now include use of the Moderna COVID-19 vaccine, and the rationales have been updated with evidence from Moderna COVID-19 vaccine clinical trials||2020-12-23|
|Recommendations||The recommendations for immunosuppressed individuals and those with autoimmune conditions have been split into two separate recommendations and further rationale for the recommendations has been provided.||2020-12-23|
|Recommendations||Additional information has been added to the rationale for the recommendation on pregnancy and breastfeeding and now recommends that it would be prudent to delay pregnancy by at least 28 days after the completion of a two-dose series of mRNA COVID-19 vaccines.||2020-12-23|
|Appendix B||Evidence on the efficacy, immunogenicity, and safety of the Moderna COVID-19 vaccine has been added in a new appendix||2020-12-23|
|Appendix C||Application of the EEFA Framework: Ethical analysis of the options for the delivery of a second dose of COVID-19 vaccine in the context of a limited vaccine supply has been added in a new appendix||2020-12-23|
|Appendix D||Frequency of Solicited Adverse Events Following Immunization for COVID-19 vaccine has been added in a new appendix||2020-12-23|
Recommendations on the use of COVID-19 vaccine(s) (version now archived)
The first version of the evergreen document was published outlining the recommendations for use of the Pfizer BioNTech COVID-19 vaccine.
Published December 12, 2020
|Contraindications and Precautions||
Reinforced existing recommendation that the authorized COVID-19 vaccines are contraindicated in individuals with a history of anaphylaxis after previous administration of the vaccine and included a new table with vaccine components that are potential allergens known to cause type 1 hypersensitivity reactions
Report a problem or mistake on this page
- Date modified: